🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

I'm excited to be moderating a panel at #SynBioBeta2025 on the present and future of tech-enabled protein engineering. Got any burning questions? Drop them below. Will you be there in person? Send me a DM! I'd love to chat while I'm there.

I'm generally a fan of improving access to preventive health services. Given price elasticity for out-of-pocket services like full-body MRI, the massive price decrease here is a boon. Still, I've been cautious about full-body MRI in ostensibly very healthy sub-populations.

Starting the annual harvest of synthetic lethality memes ahead of #ASCO25

Does anyone know Leo XIV’s stance on onc approvals using surrogate endpoints? Asking for a friend

Excellent article, already forwarded to several friends in biotech. For innovators bringing new therapies to patients, engaging with payers, physicians, and patients feels like a smaller part of a long (scientific) journey. But it still matters! It turns out understanding what

From a new great post by Simon Barnett DIMENSION on TPPs (link below). Sharing this because, although this may sound extremely obvious, I am always surprised by the answers companies give for why they chose a certain target / indication, which often doesn't include the

Resurfacing this old post following Regeneron's acquisition of 23andMe. As many have pointed out, the $256M acquisition price crudely approximates the value / record at $17. Even if these records were full genomes, I'm not sure the price would be much higher. I'm hopeful

Propranolol is also the only FDA-approved therapy for essential tremor. It has about a 40% disease control rate, but unfortunately many patients come off of it given fatigue and bradycardia. Breaking the “steady, but sleepy” paradigm is essential for next-gen ET drugs!

The DIMENSION team will be at #ASCO25 ~ feel free to DM if you’d like to chat all things oncology, targets, new modalities, etc!